Some cancer docs still bill heavily for Amgen's Epogen despite safety questions

Many cancer doctors have cut back on their use of Amgen's ($AMGN) anemia drug Epogen--also sold as Procrit by Johnson & Johnson ($JNJ)--because of safety questions that arose over the past few years. But as The Wall Street Journal reports, one Florida doctors' group still administers the drug in quantity, accounting for one-sixth of related Medicare charges in 2012. Report (sub. req.)

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.